-
Mashup Score: 5
A high dose of upadacitinib resulted in a meaningful clinical response in a study of several patients with long-standing recalcitrant granulomatous cheilitis.
Source: www.medscape.comCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 0Upadacitinib Outperforms Dupilumab in Primary and Secondary End Points in Head-to-Head AD Study - 8 month(s) ago
In LEVEL-UP, upadacitinib demonstrated superiority over dupilumab in achieving EASI-90 and little to no itch at week 16.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
NEW TODAY: AbbVie announced topline data from its LEVEL-UP study evaluating the safety and efficacy of #upadacitinib 15mg once daily compared to dupilumab in adolescent and adult patients with moderate to severe AD and inadequate responses to systemics. https://t.co/DdQerV2zWe
-
-
Mashup Score: 65-Year Safety Data From Upadacitinib Trials Reported - 1 year(s) ago
Upadacitinib trials in atopic dermatitis have included diverse patient groups with varying risk factors, according to Dr Christopher Bunick.
Source: www.medscape.comCategories: General Medicine News, Allergy-ImmunologyTweet-
5-Year Safety Data From #Upadacitinib Trials Reported https://t.co/hC6qL5YuS0
-
-
Mashup Score: 1
Achievement of minimal disease activity and remission were observed in approximately half of patients with psoriatic arthritis receiving upadacitinib.
Source: www.hcplive.comCategories: Latest Headlines, RheumatologyTweet-
Achievement of minimal disease activity and remission were observed in approximately half of patients with #PsoriaticArthritis receiving #upadacitinib. https://t.co/XW5IyVvcfj
-
-
Mashup Score: 0
Adolescents with moderate-to-severe atopic dermatitis (AD) saw major improvements after taking upadacitinib (Rinvoq) for 16 weeks, according to an analysis appearing recently in . The study combined data from three separate phase 3 studies, collectively taking place in more than 20 countries and comprising 552 adolescents (290 female; 262 male).
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
What did the data indicate regarding #upadacitinib use in this adolescent population? #AtopicDermatitis #AADReadingRoom @AADskin #dermatology Read more: https://t.co/IuictqUOAP https://t.co/DWWAho7VZE
-
-
Mashup Score: 0Continuous Upadacitinib Treatment of Atopic Dermatitis Suggested to Ensure Maintenance of Skin Clearance - 1 year(s) ago
In this latest research, the investigators noted that upadacitinib therapy may also be utilized as a treatment option for atopic dermatitis patients who experience a flare.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet-
New research showed that discontinuation of #upadacitinib followed by reintroduction for adults with #AtopicDermatitis leads to diminished results followed by rapid recovery: https://t.co/UriDv8Tbcn
-
-
Mashup Score: 0
Although major adverse cardiac events, malignancy and venous thromboembolism are more frequent in at-risk patients with rheumatoid arthritis, rates are similar between those receiving upadacitinib vs. adalimumab, according to data.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
Although major adverse ❤️cardiac events, malignancy and venous thromboembolism are more frequent in at-risk patients with rheumatoid #arthritis, rates are similar between those receiving #upadacitinib vs. #adalimumab https://t.co/9oy7YiZ7vH
-
-
Mashup Score: 0
In a recent study published in RMD Open, the long-term safety profile of upadacitinib, a medication utilized in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD), was evaluated.
Source: HMP Global Learning NetworkCategories: Dermatology, Latest HeadlinesTweet-
In a recent study, the long-term safety profile of upadacitinib, a medication utilized in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and atopic dermatitis, was evaluated. https://t.co/OANkYuQPzE #dermtwitter #dermatology #upadacitinib
-
-
Mashup Score: 0Roy Fleischmann, MD: Long-Term Safety, Efficacy of Upadacitinib for Rheumatoid Arthritis Treatment - 2 year(s) ago
Results found all clinical and patient-reported responses were statistically better with upadacitinib plus methotrexate compared with adalimumab plus methotrexate, although both treatments were effective.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Results found all clinical and patient-reported responses were statistically better with #upadacitinib plus methotrexate compared with #adalimumab plus methotrexate, although both treatments were effective. https://t.co/rR0RAcoYvj #RheumatoidArthritis #EULAR2023
-
-
Mashup Score: 0Iain McInnes, CBE, PhD: Long-Term Efficacy, Safety of Upadacitinib in Patients With Psoriatic Arthritis - 2 year(s) ago
Over a 3-year period, patients treated with upadacitinib reported greater disease improvements and a greater mean change from baseline when compared with those receiving adalimumab.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
ICYMI: Over a 3-year period, patients treated with #upadacitinib reported greater disease improvements and a greater mean change from baseline when compared with those receiving adalimumab: https://t.co/8L74vqFI85 #EULAR2023 #PsoriaticArthritis
-
A high dose of #upadacitinib resulted in a meaningful clinical response in a study of several patients with long-standing recalcitrant granulomatous cheilitis. https://t.co/xTObg88H7D